ASH is continually re-assessing the status of our upcoming meetings in light of the COVID-19 global health crisis. We encourage you to monitor the webpages for individual ASH meetings to stay abreast of the latest updates.
Please note: The 62nd ASH Annual Meeting will be all-virtual. Learn more
Upcoming ASH Meetings
ASH offers premier educational and scientific meetings and workshops for hematology professionals worldwide. Browse the ASH events below to find your next hematology meeting.
ASH Annual Meeting & Exposition
December 5-8, 2020
Attend the world’s most comprehensive hematology event of the year for an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.
Highlights of ASH®
Nine locations, one great program
Learn how new clinical research presented at the latest ASH annual meeting will influence hematology patient care. Attend one of nine meetings worldwide.
ASH Meeting on Lymphoma Biology
Further your understanding of lymphoma pathogenesis and therapy through scientific exchange based on basic and translational research in lymphoma and lymphoma malignancies.
Sickle Cell Disease Workshop
February 16-19, 2020
A workshop to train health care professionals in some of the skills necessary to establish a center focused on the needs of adults living with SCD.
ASH Meeting on Hematologic Malignancies
August 27 - September 12, 2020
"How I Treat" presentations are the focus of this meeting, which features the top experts in hematologic malignancies in an intimate setting with no competing sessions.
ASH Consultative Hematology Course
September 10, 2020
December 7, 2020
Update your core knowledge of non-malignant hematology by attending this interactive, half-day course intended for clinical hematologists based in community practice in North America.
ASH Summit on Immunotherapies for Hematologic Diseases
April 1-2, 2021
Omni Shoreham, Washington, DC
Gain insights into the critical limitations of immunotherapies, explore ways in which these therapies can be improved for widespread use in patients with hematologic malignancies and learn about the application of immunotherapies for the treatment of non-malignant hematologic diseases.